GLP-1 agonist liraglutide improves ouabain-induced mania and depressive state <i>via</i> GSK-3β pathway

Çiçekli, Mustafa Nusret; Tiryaki, Emre Soner; Altun, Ahmet; Günaydın, Caner

doi:10.1080/10799893.2022.2032747

Cited by 5 publications

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A review and metaanalysis suggest that it significantly reduces depressive symptoms in diabetic patients [16]. Animal studies suggest that the underlying mechanisms may involve the activation of the GLP-1 receptor, which suppresses microglial proptosis by promoting mitophagy, thereby reducing depressionlike symptoms in diabetic mice [17] and promoting glyco-gen synthase kinase-3 beta (GSK-3β ) phosphorylation [18]. Reports of liraglutide-associated depression are limited, particularly among individuals with obesity and comorbid diabetes.…”

Section: Discussionmentioning

confidence: 99%

Liraglutide-Induced Depression with Suicidality in an Obese Adult: A Case Report

M. Almarshad,

Ram

2024

Galician med. j.

View full text Add to dashboard Cite

Obesity is a major health issue worldwide. Treating adults with obesity often involves lifestyle and diet changes and sometimes medication. Liraglutide is a drug that is being closely studied for treating obesity. However, the potential side effects of liraglutide, particularly its impact on mood and the development of depression, may be of concern. Given the frequent co-occurrence of obesity and depression, it is important to understand how obesity treatments like liraglutide might affect a person’s mood. A 47-year-old schoolteacher with no personal or family history of mental illness or chronic physical condition sought help for his steadily increasing weight. Despite having a sedentary job and reporting no major stress or substance use, he did not attempt to change his diet or activity level, occasionally experiencing sleep difficulties. He was overweight, with a body mass index of 42. The patient was diagnosed with adult obesity and prescribed liraglutide, diet changes, and exercise. Initially, he lost weight, but he also developed depressive symptoms, including fatigue, loss of interest, sleep disturbances, and suicidal ideation. Following cessation of liraglutide treatment, his depression symptoms got better, but his weight slightly increased. This case sheds light on the possible link between liraglutide and depression in managing obesity. It is crucial for healthcare providers to be aware of potential mental health side effects of obesity drugs like liraglutide. Although the exact reasons behind these mood changes are not fully understood, this case emphasizes the need for careful observation and decision-making in treatment. Understanding these issues can help balance the benefits and risks of liraglutide and ensure better care and treatment options for people with obesity.

show abstract

Section: Discussionmentioning

confidence: 99%

Liraglutide-Induced Depression with Suicidality in an Obese Adult: A Case Report

M. Almarshad,

Ram

2024

Galician med. j.

View full text Add to dashboard Cite

show abstract

“…7 Human trials have also yielded promising results, with several clinical studies reporting improvements in depressive symptoms following treatment with GLP-1 RAs. 8,9 Moreover, preliminary evidence suggests potential benefits in conditions such as bipolar disorder and schizophrenia, hinting at the broad spectrum of psychiatric disorders that could potentially benefit from GLP-1-based Sasidhar Gunturu 1 Gunturu interventions 10 Recent discoveries and incidental findings primarily observed in diabetic patients treated with GLP-1 RAs present an intriguing avenue for exploration. While these developments are undoubtedly exciting, the definitive role or mechanism of action has not yet been firmly established; instead, they remain the subject of hypothesis and conjecture.…”

Section: Glp-1 Agonists In Psychiatric Disordersmentioning

confidence: 99%

The Potential Role of GLP-1 Agonists in Psychiatric Disorders: A Paradigm Shift in Mental Health Treatment

Gunturu

2024

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

Liraglutide and Naringenin relieve depressive symptoms in mice by enhancing Neurogenesis and reducing inflammation

Abdelkawy,

Elharoun,

Sheta

et al. 2024

European Journal of Pharmacology

View full text Add to dashboard Cite

GLP-1 agonist liraglutide improves ouabain-induced mania and depressive state via GSK-3β pathway

Cited by 5 publications

References 45 publications

Liraglutide-Induced Depression with Suicidality in an Obese Adult: A Case Report

Liraglutide-Induced Depression with Suicidality in an Obese Adult: A Case Report

The Potential Role of GLP-1 Agonists in Psychiatric Disorders: A Paradigm Shift in Mental Health Treatment

Liraglutide and Naringenin relieve depressive symptoms in mice by enhancing Neurogenesis and reducing inflammation

Contact Info

Product

Resources

About